Assembly Biosciences is advancing a new class of oral therapeutics for the treatment of hepatitis B (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
- Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
Aug 6, 2020 at 10:00 AM EDT
Jul 20, 2020 at 8:30 AM EDT
Jun 22 - Jun 24, 2020